荃信生物：与罗氏达成QX031N的全球独家许可协议

Core Insights - The article reports that Qianxin Biotech has entered into a global exclusive collaboration and licensing agreement with Roche Pharmaceuticals for the development and commercialization of QX031N, a long-acting dual-specific antibody [1] Financial Terms - The agreement includes an upfront payment of $75 million, potential milestone payments of up to $995 million, and tiered royalties [1] Product Details - QX031N targets TSLP and IL-33, proteins involved in the development of respiratory diseases and play a significant role in the inflammatory process [1] - The antibody is expected to provide a new treatment option for respiratory diseases such as COPD and asthma [1]